Samuel Obeng

Samuel Obeng, Ph.D.

Assistant Scientist

Department: Medicinal Chemistry
Business Email: obengs@ufl.edu

About Samuel Obeng

Samuel Obeng, Ph.D., was appointed as an assistant scientist in the College of Pharmacy, Department of Pharmacodynamics in July 2019. Obeng received his Bachelor of Pharmacy and M.Phil. Pharmaceutical Chemistry degrees from Kwame Nkrumah University of Science and Technology, and his Ph.D. in Medicinal Chemistry from Virginia Commonwealth University, Department of Medicinal Chemistry. Upon completion of his doctoral studies, Obeng completed a 1-year postdoctoral fellowship under the supervision of Dr. Yan Zhang and Dr. Dana Selley in the Departments of Medicinal Chemistry and of Pharmacology and Toxicology at Virginia Commonwealth University. Obeng then joined the University of Florida College of Pharmacy in July 2018 as a postdoctoral research associate in the Department of Pharmacodynamics working in both Dr. Lance McMahon and Dr. Christopher McCurdy’s laboratories. Obeng has keen interest in the design, discovery and development of novel opioid ligands for the treatment of pain and opioid use disorder.

Teaching Profile

Courses Taught
2020
PHA6935 Selected Topics in Pharmacy

Publications

2022
Design, Synthesis, and Biological Evaluation of NAP Isosteres: A Switch from Peripheral to Central Nervous System Acting Mu-Opioid Receptor Antagonists.
Journal of medicinal chemistry. 65(6):5095-5112 [DOI] 10.1021/acs.jmedchem.2c00087. [PMID] 35255685.
2022
In vitro and in vivo pharmacology of kratom.
Advances in pharmacology (San Diego, Calif.). 93:35-76 [DOI] 10.1016/bs.apha.2021.10.001. [PMID] 35341571.
2022
Slow conformational dynamics of the human A2A adenosine receptor are temporally ordered.
Structure (London, England : 1993). 30(3):329-337.e5 [DOI] 10.1016/j.str.2021.11.005. [PMID] 34895472.
2021
Activity of Mitragyna speciosa (“Kratom”) Alkaloids at Serotonin Receptors.
Journal of medicinal chemistry. 64(18):13510-13523 [DOI] 10.1021/acs.jmedchem.1c00726. [PMID] 34467758.
2021
Correction to “Novel Approaches, Drug Candidates, and Targets in Pain Drug Discovery”.
Journal of medicinal chemistry. 64(15) [DOI] 10.1021/acs.jmedchem.1c01159. [PMID] 34264657.
2021
Novel Approaches, Drug Candidates, and Targets in Pain Drug Discovery.
Journal of medicinal chemistry. 64(10):6523-6548 [DOI] 10.1021/acs.jmedchem.1c00028. [PMID] 33956427.
2021
Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for μ-Opioid Receptor and Opioid-Like Behavioral Effects in Rats.
The Journal of pharmacology and experimental therapeutics. 376(3):410-427 [DOI] 10.1124/jpet.120.000189. [PMID] 33384303.
2020
Design and synthesis of a bivalent probe targeting the putative mu opioid receptor and chemokine receptor CXCR4 heterodimer
RSC Medicinal Chemistry. 11(1):125-131 [DOI] 10.1039/c9md00433e. [PMID] 33479612.
2020
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.
Journal of medicinal chemistry. 63(1):433-439 [DOI] 10.1021/acs.jmedchem.9b01465. [PMID] 31834797.
2020
Kappa opioid receptors mediate an initial aversive component of paclitaxel-induced neuropathy.
Psychopharmacology. 237(9):2777-2793 [DOI] 10.1007/s00213-020-05572-2. [PMID] 32529265.
2019
Application of Bivalent Bioisostere Concept on Design and Discovery of Potent Opioid Receptor Modulators
Journal of Medicinal Chemistry. 62(24):11399-11415 [DOI] 10.1021/acs.jmedchem.9b01767.
2019
Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment
ACS Chemical Neuroscience. 10(5):2518-2532 [DOI] 10.1021/acschemneuro.9b00038. [PMID] 30758946.
2019
Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4′-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands
Journal of Medicinal Chemistry. 62(2):561-574 [DOI] 10.1021/acs.jmedchem.8b01158. [PMID] 30608693.
2019
Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats
Neuropharmacology. 150:200-209 [DOI] 10.1016/j.neuropharm.2019.01.020. [PMID] 30660628.
2019
Pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3′-fluoro-4′-pyridyl)acetamido]morphinan (NFP) as a dual selective MOR/KOR ligand with potential applications in treating opioid use disorder.
European journal of pharmacology. 865 [DOI] 10.1016/j.ejphar.2019.172812. [PMID] 31743739.
2019
Role of mu-opioid agonist efficacy on antinociceptive interactions between mu agonists and the nociceptin opioid peptide agonist Ro 64-6198 in rhesus monkeys.
European journal of pharmacology. 844:175-182 [DOI] 10.1016/j.ejphar.2018.12.021. [PMID] 30552903.
2019
Structure–Activity Relationship Studies of 6α- and 6β-Indolylacetamidonaltrexamine Derivatives as Bitopic Mu Opioid Receptor Modulators and Elaboration of the “Message-Address Concept” To Comprehend Their Functional Conversion
ACS Chemical Neuroscience. 10(3):1075-1090 [DOI] 10.1021/acschemneuro.8b00349. [PMID] 30156823.
2019
The effects of mitragynine and morphine on schedule-controlled responding and antinociception in rats.
Psychopharmacology. 236(9):2725-2734 [DOI] 10.1007/s00213-019-05247-7. [PMID] 31098655.
2018
Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys.
The Journal of pharmacology and experimental therapeutics. 365(1):37-47 [DOI] 10.1124/jpet.117.246439. [PMID] 29330156.
2018
In vitro and in vivo functional profile characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan (NAQ) as a low efficacy mu opioid receptor modulator.
European journal of pharmacology. 827:32-40 [DOI] 10.1016/j.ejphar.2018.03.013. [PMID] 29530590.
2018
Methylation Products of 6β- N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators.
ACS chemical neuroscience. 9(12):3028-3037 [DOI] 10.1021/acschemneuro.8b00234. [PMID] 30001114.
2016
Antinociceptive Interactions between the Imidazoline I2 Receptor Agonist 2-BFI and Opioids in Rats: Role of Efficacy at the μ-Opioid Receptor.
The Journal of pharmacology and experimental therapeutics. 357(3):509-19 [DOI] 10.1124/jpet.116.232421. [PMID] 27056847.

Contact Details

Emails:
Business:
obengs@ufl.edu
Addresses:
Business Mailing:
PO Box 100487
GAINESVILLE FL 32610
Business Street:
1345 CENTER DR
GAINESVILLE FL 32610